Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving EyePoint, Inc. (NASDAQ: EYPT) and certain of its officers or directors on behalf of investors. The investigation follows a significant drop in the company's stock price after it announced disappointing results from its Phase 3 clinical trial for DURAVYU™. On August 17, 2026, EyePoint reported that the topline data from the LUGANO trial did not meet expectations compared to Regeneron Pharmaceuticals' (REGN) Eylea. This led to a sharp decline in its stock price by $9.88 per share or 66.98%, closing at $4.87. Pomerantz LLP, known for leading class action litigation cases, is seeking investors who may be interested in joining the potential class action lawsuit.
